These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2460975)

  • 1. Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW
    Steroids; 1987; 50(1-3):191-200. PubMed ID: 2460975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors for male infertility.
    Raman JD; Schlegel PN
    J Urol; 2002 Feb; 167(2 Pt 1):624-9. PubMed ID: 11792932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
    Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
    Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic efficacy of testolactone (aromatase inhibitor) to oligozoospermia with high estradiol/testosterone ratio].
    Itoh N; Kumamoto Y; Maruta H; Tsukamoto T; Takagi Y; Mikuma N; Nanbu A; Tachiki H
    Nihon Hinyokika Gakkai Zasshi; 1991 Feb; 82(2):204-9. PubMed ID: 2041267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover.
    Clark RV; Sherins RJ
    J Androl; 1989; 10(3):240-7. PubMed ID: 2663800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-term therapy of oligozoospermia with the aromatase inhibitor testolactone].
    Schill WB; Reiter F; Korting HC; Schweikert HU
    Hautarzt; 1987 Jul; 38(7):395-9. PubMed ID: 3115914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism.
    Herzog AG; Klein P; Jacobs AR
    Neurology; 1998 Mar; 50(3):782-4. PubMed ID: 9521275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.
    Zumoff B; Miller LK; Strain GW
    Metabolism; 2003 Sep; 52(9):1126-8. PubMed ID: 14506617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of a treatable endocrinopathy in infertile men.
    Pavlovich CP; King P; Goldstein M; Schlegel PN
    J Urol; 2001 Mar; 165(3):837-41. PubMed ID: 11176482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of androgens in human benign prostatic hyperplasia: aromatase and its inhibition.
    Bartsch W; Klein H; Stürenburg HJ; Voigt KD
    J Steroid Biochem; 1987; 27(1-3):557-64. PubMed ID: 2447391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of estrogen deprivation on human benign prostatic hyperplasia.
    Schweikert HU; Tunn UW; Habenicht UF; Arnold J; Senge T; Schulze H; Schröder FH; Blom JH; Ennemoser O; Horniger W
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):573-6. PubMed ID: 7682839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aromatase inhibitor, TZA-2209, on the prostate of androstenedione-treated castrated dogs: changes in prostate volume and histopathological findings.
    Suzuki K; Ito K; Tamura Y; Suzuki T; Honma S; Yamanaka H
    Prostate; 1996 May; 28(5):328-37. PubMed ID: 8610061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibition by delta 1-testolactone does not relieve the gonadotropin-induced late steroidogenic block in normal men.
    Smals AG; Dony JM; Smals AE; Pieters GF; Hermus AR; Boers GH; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1127-31. PubMed ID: 3923019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome.
    Feuillan PP; Jones J; Cutler GB
    J Clin Endocrinol Metab; 1993 Sep; 77(3):647-51. PubMed ID: 8370686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
    Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
    J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aromatase inhibition by delta 1-testolactone on basal and luteinizing hormone-releasing hormone-stimulated pituitary and gonadal hormonal function in oligospermic men.
    Dony JM; Smals AG; Rolland R; Fauser BC; Thomas CM
    Fertil Steril; 1985 May; 43(5):787-92. PubMed ID: 3922803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity.
    Zmuda JM; Fahrenbach MC; Younkin BT; Bausserman LL; Terry RB; Catlin DH; Thompson PD
    Metabolism; 1993 Apr; 42(4):446-50. PubMed ID: 8487666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone.
    Feuillan PP; Foster CM; Pescovitz OH; Hench KD; Shawker T; Dwyer A; Malley JD; Barnes K; Loriaux DL; Cutler GB
    N Engl J Med; 1986 Oct; 315(18):1115-9. PubMed ID: 3093862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testolactone treatment of precocious puberty in McCune-Albright syndrome.
    Foster CM; Pescovitz OH; Comite F; Feuillan P; Shawker T; Loriaux DL; Cutler GB
    Acta Endocrinol (Copenh); 1985 Jun; 109(2):254-7. PubMed ID: 3925675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.